CN116322798A - 包含胃泌素释放肽受体拮抗剂的缀合物或其盐及其用途 - Google Patents

包含胃泌素释放肽受体拮抗剂的缀合物或其盐及其用途 Download PDF

Info

Publication number
CN116322798A
CN116322798A CN202180065166.XA CN202180065166A CN116322798A CN 116322798 A CN116322798 A CN 116322798A CN 202180065166 A CN202180065166 A CN 202180065166A CN 116322798 A CN116322798 A CN 116322798A
Authority
CN
China
Prior art keywords
conjugate
mice
salt
dose
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180065166.XA
Other languages
English (en)
Chinese (zh)
Inventor
朱利恩·托格
塔尼亚·斯塔洛斯
埃米·王
阿迈勒·赛义迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olanuo Pharmaceutical Diagnostic Company
Original Assignee
Orlando Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orlando Pharmaceuticals filed Critical Orlando Pharmaceuticals
Publication of CN116322798A publication Critical patent/CN116322798A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180065166.XA 2020-09-28 2021-09-22 包含胃泌素释放肽受体拮抗剂的缀合物或其盐及其用途 Pending CN116322798A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306109.8 2020-09-28
EP20306109.8A EP3973999A1 (en) 2020-09-28 2020-09-28 Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
PCT/EP2021/076107 WO2022063850A1 (en) 2020-09-28 2021-09-22 Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof

Publications (1)

Publication Number Publication Date
CN116322798A true CN116322798A (zh) 2023-06-23

Family

ID=74180915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180065166.XA Pending CN116322798A (zh) 2020-09-28 2021-09-22 包含胃泌素释放肽受体拮抗剂的缀合物或其盐及其用途

Country Status (21)

Country Link
US (1) US20230372552A1 (cg-RX-API-DMAC7.html)
EP (2) EP3973999A1 (cg-RX-API-DMAC7.html)
JP (1) JP7824281B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230078690A (cg-RX-API-DMAC7.html)
CN (1) CN116322798A (cg-RX-API-DMAC7.html)
AU (1) AU2021348219A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003690A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189680A1 (cg-RX-API-DMAC7.html)
DK (1) DK4188457T3 (cg-RX-API-DMAC7.html)
ES (1) ES2989009T3 (cg-RX-API-DMAC7.html)
FI (1) FI4188457T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241285T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068360T2 (cg-RX-API-DMAC7.html)
IL (1) IL300486A (cg-RX-API-DMAC7.html)
LT (1) LT4188457T (cg-RX-API-DMAC7.html)
PL (1) PL4188457T3 (cg-RX-API-DMAC7.html)
PT (1) PT4188457T (cg-RX-API-DMAC7.html)
RS (1) RS65994B1 (cg-RX-API-DMAC7.html)
SI (1) SI4188457T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400392T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022063850A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2026150109A1 (en) 2025-01-10 2026-07-16 Molecular Partners Ag Mesothelin-specific binding constructs and their use in radiotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101965358A (zh) * 2008-03-07 2011-02-02 巴塞尔大学医院 铃蟾肽类似肽拮抗物缀合物
US20150217006A1 (en) * 2014-02-06 2015-08-06 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
CN110678227A (zh) * 2017-01-12 2020-01-10 雷迪奥梅迪克斯股份有限公司 使用与放射性同位素螯合的奥曲肽衍生物治疗过表达生长抑素受体的癌细胞

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101965358A (zh) * 2008-03-07 2011-02-02 巴塞尔大学医院 铃蟾肽类似肽拮抗物缀合物
US20150217006A1 (en) * 2014-02-06 2015-08-06 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
CN110678227A (zh) * 2017-01-12 2020-01-10 雷迪奥梅迪克斯股份有限公司 使用与放射性同位素螯合的奥曲肽衍生物治疗过表达生长抑素受体的癌细胞

Also Published As

Publication number Publication date
EP4188457B1 (en) 2024-07-03
EP3973999A1 (en) 2022-03-30
EP4188457A1 (en) 2023-06-07
ES2989009T3 (es) 2024-11-25
JP7824281B2 (ja) 2026-03-04
PL4188457T3 (pl) 2025-01-07
AU2021348219A1 (en) 2023-03-09
WO2022063850A1 (en) 2022-03-31
LT4188457T (lt) 2024-12-27
SI4188457T1 (sl) 2025-01-31
SMT202400392T1 (it) 2024-11-15
HUE068360T2 (hu) 2024-12-28
JP2023542218A (ja) 2023-10-05
RS65994B1 (sr) 2024-10-31
BR112023003690A2 (pt) 2023-04-04
CA3189680A1 (en) 2022-03-31
DK4188457T3 (da) 2024-08-26
IL300486A (en) 2023-04-01
HRP20241285T1 (hr) 2025-01-03
US20230372552A1 (en) 2023-11-23
KR20230078690A (ko) 2023-06-02
FI4188457T3 (fi) 2024-09-23
PT4188457T (pt) 2024-09-10

Similar Documents

Publication Publication Date Title
Chen et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
RU2693465C9 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
CN113004371A (zh) 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
US5804157A (en) Peptide compositions and method of radiolabeling
KR20140053819A (ko) 방사선요법용 177루테튬-표지 봄베신 유사체
TWI893557B (zh) 一種靶向sstr2的化合物及其製備方法和應用
JP7824281B2 (ja) ガストリン放出ペプチド受容体アンタゴニストを含むコンジュゲートまたはその塩およびそれらの使用
AU2004222531A1 (en) Radiolabeled conjugates based on substance P and the uses thereof
CA2464002C (en) Pacap compositions and methods for tumor imaging and therapy
US20240100202A1 (en) Psma-targeting conjugate and uses thereof
KR101658206B1 (ko) 전립선암의 진단 및 치료를 위한 가스트린유리펩티드수용체 길항서열 기반의 신규한 봄베신 유도체 화합물
RU2821944C2 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
WO2026058257A1 (en) Grpr binding peptides
AU2002342104A1 (en) PACAP compositions and methods for tumor imaging and therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: France

Address after: French chastillon

Applicant after: Orlano Pharmaceutical Manufacturing Corp.

Address before: French chastillon

Applicant before: Orlando pharmaceuticals

Country or region before: France

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260715

Address after: France

Applicant after: Olanuo Pharmaceutical Diagnostic Company

Country or region after: France

Address before: French chastillon

Applicant before: Orlano Pharmaceutical Manufacturing Corp.

Country or region before: France